Rapid methods for the extraction of nucleic acids from biological samples
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-015/10
C12Q-001/68
출원번호
US-0152871
(2016-05-12)
등록번호
US-9976136
(2018-05-22)
발명자
/ 주소
Fischer, Gerald W.
Daum, Luke T.
출원인 / 주소
Longhorn Vaccines and Diagnostics, LLC
대리인 / 주소
Remenick PLLC
인용정보
피인용 횟수 :
1인용 특허 :
146
초록▼
The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads
The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads with a magnet or other electrical field. Liquid may be removed, or not, and an alkaline buffer is added followed by magnetic carboxy beads in a binding buffer so that nucleic acids transfer to the carboxy beads, which can be easily and quickly isolated once again with a magnet. Total nucleic acid extraction is greatly enhanced. Extracted nucleic acids can be analyzed, for example, by PCR wherein the nucleic acids can be identified and characterized. Carboxy beads may also contain a ligand so as to target specific nucleic acid sequences. The invention is also directed to kits comprising the tools and compositions for performing the methods of the invention.
대표청구항▼
1. A method of extracting nucleic acids from a biological sample containing cells and/or microorganisms comprising: adding a matrix material and a buffer to the biological sample, wherein the matrix material binds to nucleic acids of the sample;isolating matrix material bound to nucleic acids of the
1. A method of extracting nucleic acids from a biological sample containing cells and/or microorganisms comprising: adding a matrix material and a buffer to the biological sample, wherein the matrix material binds to nucleic acids of the sample;isolating matrix material bound to nucleic acids of the sample;adding an intermediate buffer that promotes a release of nucleic acids from the matrix material to form a mixture;adding a chemically modified magnetic matrix material and a binding buffer to the mixture wherein the chemically modified matrix material comprises a ligand that binds to a specific nucleic acid sequence;exposing the mixture to a magnetic field to concentrate the magnetic matrix material bound to the specific nucleic acid sequence; andadding an extraction buffer to the concentrated magnetic matrix material wherein the specific nucleic acid sequence is extracted from the magnetic matrix material. 2. The method of claim 1, wherein the biological sample comprises human, animal, microbial or plant material. 3. The method of claim 1, wherein the matrix material comprises magnetic beads of silicone, porcelain, ceramic, plastic, glass or polymer. 4. The method of claim 1, wherein the matrix material disrupts the cells and/or microorganisms of the biological sample and binds to nucleic acids released from the disrupted cells and/or microorganisms. 5. The method of claim 1, wherein the matrix material does not disrupt the cells and/or microorganisms of the biological sample and binds to nucleic acids of the biological sample other than those present within the cells and/or microorganisms. 6. The method of claim 1, wherein the buffer comprises a chaotrope, a detergent, a reducing agent, a buffer and a chelator, together at a pH of between about 6-8. 7. The method of claim 1, wherein the buffer is a lysis buffer that lyses cells, inactivates nucleases, stabilizes macromolecules, and sterilizes the sample at ambient temperatures. 8. The method of claim 1, wherein the buffer is a non-cell lysis buffer that maintains the integrity of cells and/or microbes of the biological sample. 9. The method of claim 1, wherein the intermediate buffer causes the release of nucleic acids from the matrix material and has a pH above 7. 10. The method of claim 1, wherein the intermediate buffer comprises TE, saline, an alkaline solution, NALC or a combination thereof. 11. The method of claim 1, wherein the chemical modification of the chemically modified magnetic matrix material is a carboxy group. 12. The method of claim 1, wherein the specific nucleic acid comprises a cancer marker, a sequence indicating the presence of a pathogenic organism or infection, a sequence that is characteristic of a phenotypic condition, a sequence indicating a lineage, a sequence indicating an identifiable characteristic, a sequence indicating a mutation, a sequence indicating a change from a wild-type sequence, or a combination thereof. 13. The method of claim 1, wherein the specific nucleic acid sequence is indicative of the presence of a pathogen. 14. The method of claim 13, wherein the pathogen is a virus, a bacterium, a parasite or a fungus. 15. The method of claim 1, wherein the binding buffer comprises PEG, a salt, a buffering agent, a chelator, a detergent, and an alcohol. 16. The method of claim 1, wherein the magnetic field is an electro-magnetic field. 17. The method of claim 1, wherein the extraction buffer comprise water, TE, saline, alcohol or a combination thereof. 18. The method of claim 1, wherein the extracted nucleic acids are identifiable by molecular analysis. 19. The method of claim 18, wherein the molecular analysis comprises a PCR. 20. The method of claim 1, which does not involve centrifugation or nucleic acid purification. 21. The method of claim 1, which is automated for high-throughput analysis of a plurality of biological samples. 22. The method of claim 1, wherein extraction efficiency, as measured by PCR cycle threshold, is lower as compared with extraction efficiency for a conventional extraction procedure. 23. The method of claim 22, wherein the conventional extraction procedure is a silica spin column extraction. 24. A method of extracting nucleic acids from a biological sample containing cells and/or microorganisms comprising: combining the biological sample with magnetic silicon dioxide beads and a lysis buffer to form a solution, wherein the beads bind to nucleic acids of the sample;exposing the solution to a magnetic field and removing liquid to concentrate the beads;adding an alkaline buffer to the concentrated magnetic beads to form a mixture, wherein the alkaline buffer causes the release of nucleic acids from the silicon dioxide beads;adding carboxy-modified magnetic beads in a binding buffer to the mixture wherein the carboxy-modified magnetic beads bind to a predetermined nucleic acid sequence;exposing the mixture to a magnetic field and removing liquid to isolate the carboxy-modified magnetic beads bound to the predetermined nucleic acid sequence; andeluting the predetermined nucleic acid sequences from the carboxy-modified magnetic beads using purified water and/or a Tris-EDTA buffer. 25. The method of claim 24, wherein the lysis buffer comprises a chaotrope, a detergent, a reducing agent, a buffer, and a chelator at a pH of about 6-8. 26. The method of claim 24, wherein the binding buffer comprises PEG, a salt, a buffering agent, a chelator, a detergent, NLS and an alcohol. 27. The method of claim 24, which does not involve centrifugation. 28. The method of claim 24, which is automated for high-throughput analysis of a plurality of biological samples. 29. The method of claim 24, wherein extraction efficiency, as measured by PCR cycle threshold, is lower as compared with extraction efficiency for a conventional extraction procedure. 30. The method of claim 29, wherein the conventional extraction procedure is a silica spin column extraction. 31. The method of claim 24, further comprising analyzing the isolated nucleic acids by a PCR. 32. A kit comprising: a solution that comprises a matrix material and a buffer;an intermediate buffer with a pH above 7; andcarboxy-modified magnetic beads in a binding buffer, wherein the carboxy-modified magnetic beads bind to a specific nucleic acid sequence. 33. The kit of claim 32, wherein the buffer comprises a chaotrope, a detergent, a reducing agent, a buffer and a chelator at a pH of about 6-8. 34. The kit of claim 33, wherein the buffer lyses cells, inactivates nucleases, stabilizes nucleic acids, and sterilizes the sample at ambient temperatures. 35. The kit of claim 32, wherein the buffer is a non-lysis buffer that maintains the integrity of cells and/or microbes. 36. The kit of claim 32, wherein the matrix material comprises silica dioxide beads. 37. The kit of claim 32, wherein the intermediate buffer has a pH of 8 or more. 38. The kit of claim 32, wherein the intermediate buffer has a pH of 9 or more. 39. The it of claim 32, wherein the binding buffer comprises a combination of PEG, a salt, a chelator, a detergent, NLS and an alcohol. 40. The kit of claim 32, further comprising a magnet or electromagnet. 41. The method of claim 1, which is performed in a single vessel. 42. The method of claim 24, which is performed in a single vessel.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (146)
Liav Avraham ; Hansjergen Joyce Anne ; Shimasaki Craig David, 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinic.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis process.
Gayral, Jean Pierre; Picard, Francois; Boissinot, Maurice; Bastien, Martine, Biological reagents and methods to verify the efficiency of sample preparation and nucleic acid amplification and/or detection.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Biological sample collection and transport device.
Bair, Jr., Robert Jackson; Heath, Ellen M.; Meehan, Heather; Paulsen, Kim Elayne; Wages, Jr., John M., Compositions and methods for using a solid support to purify RNA.
Cerutti Peter A. (Poly/Lausanne CHX) Bressoud Albric (Lausanne CHX), Detection of influenza a virus by polymerase chain reaction (PCR) preceded by reverse transcription of a region of the v.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Doyle Michael V. (Oakland CA) Newell Arthur D. (Orinda CA) Nunberg Jack H. (Oakland CA) White Thomas J. (Oakland CA), Human IL-2 as a vaccine adjuvant.
Hunter Kenneth W. (4401 Dresden St. Kensington MD 20895) Fischer Gerald W. (10748 Wayridge Dr. Gaithersburg MD 20879), Human monoclonal antibody reactive with polyribosylribitol phosphate.
Heller Michael J. (Encinitas CA), Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfe.
Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingston, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W., Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions.
Liav Avraham ; Shimasaki Craig D. ; Maher James F. ; Clinkscales C. Worth ; Roark Michael D., Kit for visually detecting the presence of a clinical specimen.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Liav Avraham (Denver CO) Maher James F. (Broken Arrow OK) Shimasaki Craig D. (Tulsa OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Method for visually detecting the presence of a virus in a clinical specimen.
Reece Phillip A.,AUX ; Wu Wen-Yang,AUX ; Jin Betty,AUX ; Krippner Guy Y.,AUX ; Watson Keith Geoffrey,AUX, Method of detection of influenza virus and compounds for use therein.
Turner Gregory A. (Independence MO) Maher James F. (Broken Arrow OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Methods for diagnosing human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrated for use th.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Polyurethane biological sample collection and transport device and its use.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Boom Willem R. (Amsterdam NLX) Adriaanse Henritte M. A. (Arnhem NLX) Kievits Tim (The Hague NLX) Lens Peter F. (Amsterdam NLX), Process for isolating nucleic acid.
Fell ; Jr. H. Perry (Redmond WA) Folger-Bruce Kim R. (Seattle WA) Yarnold Susan M. (Seattle WA), Production of chimeric antibodies by homologous recombination.
Crawford Jack T. (Atlanta GA) Eisenach Kathleen D. (Little Rock AR) Cave M. Donald (Little Rock AR) Bates Joseph H. (Little Rock AR), Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Judd Amrit K. (Belmont CA) Bucher Doris J. (New York NY) Popple Steven W. (Brooklyn NY), Synthetic peptides for diagnosis and prevention of influenza virus infection and their use.
Picard,Francois J.; Menard,Christian, Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection.
van Scharrenburg, Gustaaf J. M.; Brands, Rudi; de Haan, Lolke; Verweij, Willem Ronald; Wilschut, Jan C.; Agsteribbe, Etienne, Vaccines with an LTB adjuvant.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.